You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Minimal Residual Disease (MRD) positive leukemia

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

Recruiting
  • B-Cell Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Nov 28, 2023

ALL, MRD-positive, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Inotuzumab Ozogamicin)

Recruiting
  • ALL
  • +2 more
  • Inotuzumab Ozogamicin
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 14, 2023

Acute Myeloid Leukemia, Adult Trial in Germany (Midostaurin)

Terminated
  • Acute Myeloid Leukemia, Adult
  • Chemnitz, Germany
  • +3 more
Jan 20, 2022

Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease Trial in Mexico City (Bortezomib)

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +2 more
  • Mexico City, Mexico
    Hospital General de México "Dr. Eduardo Liceaga"
Jan 2, 2022

Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute Trial in Charlotte, Seattle (Clofarabine,

Terminated
Has Results
  • Minimal Residual Disease
  • +2 more
  • Charlotte, North Carolina
  • +1 more
Oct 4, 2021

Survival in Adult MRD Positive Acute Lymphoblastic Leukemia

Completed
  • Acute Lymphoblastic Leukemia
    • Brno, Czechia
    • +9 more
    Sep 12, 2022

    Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

    Recruiting
    • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 1, 2022

    MRD Detection by NGS in Pediatric B-ALL

    Completed
    • Acute Lymphoblastic Leukemia, Pediatric, Next Generation Sequencing
    • MRD
    • Hangzhou, Zhejiang, China
      The Children's Hospital of Zhejiang University School of Medicin
    Jul 25, 2023

    AML, Adult, Minimal Residual Disease Trial (MRD assessment)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • MRD assessment
    • (no location specified)
    Oct 13, 2023

    Acute Myeloid Leukemia Trial in Germany (FLYSYN)

    Completed
    • Acute Myeloid Leukemia
    • FLYSYN
    • Tuebingen, Baden-Wuerttemberg, Germany
    • +4 more
    Sep 27, 2021

    Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab

    Not yet recruiting
    • Ph+ ALL
    • +2 more
    • the usage of Olverembatinib combined with Inotuzumab Ozogamicin
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital, Chinese Acade
    Oct 30, 2022

    AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • chidamide and azacitidine
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Sep 27, 2023

    MDS, Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts, Mixed Myelodysplastic/Myeloproliferative

    Recruiting
    • Myelodysplastic Syndromes
    • +2 more
    • Stockholm, Sweden
      Department of Hematology, Karolinska University Hospital
    Mar 27, 2023

    MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With

    Not yet recruiting
    • Multiple Myeloma
    • Minimal Residual Disease
      • (no location specified)
      Nov 1, 2023

      Next-generation Sequencing in Pediatric B-ALL Children Patients

      Not yet recruiting
      • Acute Lymphoblastic Leukemia, Pediatric
      • (no location specified)
      Apr 19, 2023

      T-cell Acute Lymphoblastic Leukemia Trial in Chicago (Daratumumab / Hyaluronidase Injection)

      Recruiting
      • T-cell Acute Lymphoblastic Leukemia
      • Daratumumab / Hyaluronidase Injection
      • Chicago, Illinois
        Northwestern
      Jun 17, 2022

      Leukemia, Lymphoma Trial in Houston (Ofatumumab)

      Active, not recruiting
      • Leukemia
      • Lymphoma
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Dec 9, 2022

      Acute Lymphocytic Leukemia Trial (Inotuzumab ozogamicin)

      Not yet recruiting
      • Acute Lymphocytic Leukemia
      • Inotuzumab ozogamicin
      • (no location specified)
      Jul 11, 2022

      Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

      Recruiting
      • Leukemia, Myeloid, Acute
      • Minimal Residual Disease
        • Chapel Hill, North Carolina
          North Carolina Cancer Hospital (NCCH)
        Feb 2, 2023

        Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))

        Recruiting
        • Mixed Phenotype Acute Leukemia (MPAL)
        • Measurable Residual Disease (MRD)
        • BLINCYTO (Blinatumomab)
        • Baltimore, Maryland
          Greenebaum Cancer Center at University of Maryland Medical Cente
        Apr 18, 2022

        ALL, Recurrent, Adult Trial in Germany (Blinatumomab)

        Active, not recruiting
        • ALL, Recurrent, Adult
        • Frankfurt (Main), Hessen, Germany
        • +21 more
        Mar 16, 2022

        Pediatric ALL, B Cell, Minimal Residual Disease Trial in Seoul (Blinatumomab for Injection)

        Recruiting
        • Pediatric ALL, B Cell
        • Minimal Residual Disease
        • Blinatumomab for Injection
        • Seoul, Korea, Republic of
          Seoul National University Hospital
        Feb 20, 2022

        Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou

        Not yet recruiting
        • Minimal Residual Disease
        • Esophageal Squamous Cell Carcinoma
          • Guangzhou, Guangdong, China
            Guangdong Provincial People's Hospital
          Jun 10, 2023

          Multiple Myeloma Trial (Dexamethasone, Isatuximab, Lenalidomide)

          Not yet recruiting
          • Multiple Myeloma
          • (no location specified)
          Jan 10, 2023

          Using Mass Spectrometry Detecting Minimal Residual Disease in

          Recruiting
          • Multiple Myeloma
            • Tianjin, China
              InsituteHBDH
            Sep 8, 2022